Overview

Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2025-01-20

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Pembrolizumab